CameroonTuberculosis profile
Population  2015 23 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 6.9 (4.1–10) 30 (18–45)
Mortality (HIV+TB only) 6.2 (3.4–9.7) 27 (15–42)
Incidence  (includes HIV+TB) 49 (32–71) 212 (137–303)
Incidence (HIV+TB only) 18 (11–26) 76 (48–110)
Incidence (MDR/RR-TB)** 1.9 (0.87–3) 8.1 (3.7–13)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 3.8 (2.2–5.3) 18 (8–27) 21 (10–32)
Males 2.5 (1.5–3.4) 26 (18–34) 28 (19–37)
Total 6.2 (4–8.4) 43 (32–54) 49 (32–71)
TB case notifications, 2015  
Total cases notified 26 570
Total new and relapse 26 117
          - % tested with rapid diagnostics at time of diagnosis 2%
          - % with known HIV status 92%
          - % pulmonary 84%
          - % bacteriologically confirmed among pulmonary 74%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 53% (37–82)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.28 (0.16–0.45)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 8 606 36%
          - on antiretroviral therapy 6 885 80%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  890
(510–1 300)
Estimated % of TB cases with MDR/RR-TB 3.2% (1.4–5) 14% (6.9–21)  
% notified tested for rifampicin resistance <1% 42% 665
MDR/RR-TB cases tested for resistance to second-line drugs   122
Laboratory-confirmed cases MDR/RR-TB: 122, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 122, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 84% 26 022
Previously treated cases, excluding relapse, registered in 2014 65% 489
HIV-positive TB cases, all types, registered in 2014 78% 8 731
MDR/RR-TB cases started on second-line treatment in 2013 92% 76
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
2.6% (2.4–2.8)
TB financing, 2016  
National TB budget (US$ millions) 5.1
Funding source: 27% domestic, 73% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-08 Data: www.who.int/tb/data